Navigation Links
Luminex Corporation To Host Investor Event December 11, 2012
Date:11/27/2012

AUSTIN, Texas, Nov. 27, 2012 /PRNewswire/ -- Luminex Corporation (NASDAQ: LMNX) will host an investor event in New York City on Tuesday, December 11, 2012 beginning at 8am ET, as previously announced on its third quarter financial results conference call.  

(Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO)

Patrick J. Balthrop, president and chief executive officer, and other members of the executive management team will provide insight into the company's long-term strategic plans with a focus on its molecular diagnostic product pipeline.Advanced registration is required and attendance will be limited to those registered. To register, please contact Matthew Scalo, Senior Director of Investor Relations. Breakfast will be served beginning at 7am ET.

The presentation will be webcast live and may be accessed at Luminex Corporation's website at http://www.luminexcorp.com. Simply log on to the web at the address above, go to the Company section and access the Investor Relations link.  Please go to the website at least 15 minutes prior to the event to register, download and install any necessary audio/video software. If you are unable to participate during the live webcast, the presentation will be archived on the website using the 'replay' link.

Luminex is committed to applying its passion for innovation toward advancing healthcare and research worldwide. We are transforming global healthcare and life-science research through the development, manufacturing, and marketing of proprietary instruments and assays utilizing our xMAP® open-architecture, multi-analyte platform and our MultiCode® real-time polymerase chain reaction (PCR) and multiplex PCR-based technologies that deliver cost-effective and rapid results to clinicians and researchers. Our technology is commercially available worldwide and in use in leading clinical laboratories as well as major pharmaceutical, diagnostic, biotechnology and life-science companies.  We are meeting the needs of customers in markets as diverse as clinical diagnostics, pharmaceutical drug discovery, biomedical research including genomic and proteomic research, personalized medicine, bio-defense research and food safety.  For further information on Luminex Corporation and the latest advances in multiplexing using award winning technology please visit our website at http://www.luminexcorp.com.Contacts:

Matthew ScaloSr. Director of Investor Relations512-219-8020mscalo@luminexcorp.com 


'/>"/>
SOURCE Luminex Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Luminex Corporation to Present at JP Morgan Healthcare Conference
2. Luminex Corporation Fourth Quarter and Full Year 2011 Earnings Release Scheduled for February 6, 2012
3. Luminex Corporation to Speak at Joint Department of Defense and Environmental Protection Agency 5th National Bio-Threat Conference
4. Luminex Corporation Receives CE Mark for Revolutionary Newborn Screening Platform
5. Luminex Corporation to Present at Jefferies 2012 Global Healthcare Conference
6. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2012 Financial Results
7. Kensey Nash Corporation Announces Achievement of $6 Million Milestone From Spectranetics Corporation
8. China Cord Blood Corporation Announces Results of 2011 Annual General Meeting
9. Neogen Corporation Announces 2nd Quarter Results Conference Call
10. Plaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
11. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... (PRWEB) , ... April 18, 2017 , ... ... 1970s and has been a key device for generating monodisperse droplets of known ... droplet processes and for generating monodisperse solid particles by drying monodisperse droplets. ...
(Date:4/19/2017)... ... 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 ... Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. ... assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. ...
(Date:4/19/2017)... Oregon and PUNE, India , April 19, 2017 ... "Membrane Microfiltration Market: Global Opportunity Analysis and Industry Forecast, 2014-2022 ," the ... garner $12,858 million by 2022, registering a CAGR of 9.6% from 2016 to ... ... ...
(Date:4/19/2017)... April 19, 2017   Thermo Fisher Scientific ... multi-center Procalcitonin MOnitoring SEpsis (MOSES) Study have been ... Critical Care Medicine . Researchers from the ... Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring ... B·R·A·H·M·S PCT (procalcitonin) assay to assess risk for ...
Breaking Biology Technology:
(Date:3/20/2017)... , March 20, 2017 PMD Healthcare announces ... spirometer and Wellness Management System (WMS), a remote, real-time ... in 2010, PMD Healthcare is a Medical Device, Digital ... mission dedicated to creating innovative solutions that empower people ... that intent focus, PMD developed the first ever personal ...
(Date:3/9/2017)... Australia , March 9, 2017 ... the prestigious World Lung Imaging Workshop at the University ... , was invited to deliver the latest data to ... globally recognised event brings together leaders at the forefront ... developments in lung imaging. "The quality ...
(Date:3/7/2017)... March 7, 2017   HireVue , the leading ... companies identify the best talent, faster, today announced the ... Officer (CSO) and Diana Kucer as Chief ... seasoned executive team poised to drive continued growth in ... a year of record bookings in 2017. ...
Breaking Biology News(10 mins):